Elevated serum and synovial fluid (SF) fractalkine (CX3CL1) levels have been detected in patients with knee osteoarthritis (OA). The current study was carried out to investigate the association between serum and SF fractalkine levels with symptomatic severity in patients with knee OA.
Method
One hundred ninety-three patients with OA and 182 healthy controls were enrolled in this study. The symptomatic severity was assessed by the Western Ontario McMaster University Osteoarthritis scores.
Results
Fractalkine levels in SF and serum were both positively associated with self-reported greater pain and physical disability.
Conclusions
Fractalkine in SF and serum may serve as a biomarker for reflecting symptomatic severity. Therapeutic interventions that target fractalkine signaling pathways to delay OA-related symptoms deserve further study.
FelsonDT, NaimarkA, AndersonJ, . The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987; 30: 914–922.
2.
BijlsmaJW, BerenbaumF, LafeberFP.Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011; 377: 2115–2126.
3.
KrausVB, BurnettB, CoindreauJ, . Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011; 19: 515–542.
4.
HaywoodL, McWilliamsDF, PearsonCI, . Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 2003; 48: 2173–2174.
5.
BenitoMJ, VealeDJ, FitzGeraldO, . Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005; 64: 1263–1267.
6.
WolfeF.The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol. 1997; 24: 1486–1488.
7.
StannusO, JonesG, CicuttiniF, . Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage. 2010; 18: 1441–1447.
8.
WojdasiewiczP, PoniatowskiLA, SzukiewiczD.The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014; 2014: 56–59.
9.
GerardC, RollinsBJ.Chemokines and disease. Nat Immunol. 2001; 2: 108–115.
BazanJF, BaconKB, HardimanG, . A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385: 640–644.
12.
KlosowskaK, VolinMV, HuynhN, . Fractalkine functions as a chemoattractant for osteoarthritis synovial fibroblasts and stimulates phosphorylation of mitogen-activated protein kinases and Akt. Clin Exp Immunol. 2009; 156: 312–319.
13.
SandellLJ, XingX, FranzC, . Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage. 2008; 16: 1560–1571.
14.
IsozakiT, KasamaT, TakahashiR, . Synergistic induction of CX3CL1 by TNF alpha and IFN gamma in osteoblasts from rheumatoid arthritis: involvement of NF-kappa B and STAT-1 signaling pathways. J Inflamm Res. 2008; 1: 19–28.
15.
YanoR, YamamuraM, SunahoriK, . Recruitment of CD16+ monocytes into synovial tissues is mediated by fractalkine and CX3CR1 in rheumatoid arthritis patients. Acta Med Okayama. 2007; 61: 89–98.
16.
LeonovA, TrofimovS, ErmakovS, . Quantitative genetic study of amphiregulin and fractalkine circulating levels—potential markers of arthropathies. Osteoarthritis Cartilage. 2011; 19: 736–742.
17.
ZouY, LiY, LuL, . Correlation of fractalkine concentrations in serum and synovial fluid with the radiographic severity of knee osteoarthritis. Ann Clin Biochem. 2013; 50: 571–575.
18.
ClarkAK, StanilandAA, MalcangioM.Fractalkine/CX3CR1 signalling in chronic pain and inflammation. Curr Pharm Biotechnol. 2011; 12: 1707–1714.
19.
AltmanR, AschE, BlochD, . Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986; 29: 1039–1049.
20.
RingdahlE, PanditS.Treatment of knee osteoarthritis. Am Fam Physician. 2011; 83: 1287–1292.
21.
BellamyN, BuchananWW, GoldsmithCH, . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15: 1833–1840.
22.
GandhiR, RazakF, DaveyJR, . Metabolic syndrome and the functional outcomes of hip and knee arthroplasty. J Rheumatol. 2010; 37: 1917–1922.
23.
KellgrenJH, LawrenceJS.Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957; 16: 494–502.
24.
PatraD, SandellLJ.Recent advances in biomarkers in osteoarthritis. Curr Opin Rheumatol. 2011; 23: 465–470.
25.
HaseebA, HaqqiTM.Immunopathogenesis of osteoarthritis. Clin Immunol. 2013; 146: 185–196.
26.
SokoloveJ, LepusCM.Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis. 2013; 5: 77–94.
27.
ChevalierX, EymardF, RichetteP.Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol. 2013; 9: 400–410.
28.
ScanzelloCR, GoldringSR.The role of synovitis in osteoarthritis pathogenesis. Bone. 2012; 51: 249–257.
29.
BaddourVT, BradleyJD.Clinical assessment and significance of inflammation in knee osteoarthritis. Curr Rheumatol Rep. 1999; 1: 59–63.
30.
SzekaneczZ, KimJ, KochAE.Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol. 2003; 15: 15–21.
31.
MortierA, Van DammeJ, Proost P. Overview of the mechanisms regulating chemokine activity and availability. Immunol Lett. 2012; 145: 2–9.
32.
RichmondA.Chemokine research moves on. Exp Cell Res. 2011; 317: 553–555.
33.
RuthJH, VolinMV, HainesGK, . Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001; 4: 1568–1581.
34.
VolinMV, HuynhN, KlosowskaK, . Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum. 2007; 56: 2512–2522.
35.
VolinMV, WoodsJM, AminMA, . Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol. 2001; 159: 1521–1530.
36.
BlaschkeS, KoziolekM, SchwarzA, . Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003; 30: 1918–1927.
37.
MuehlhoeferA, SaubermannLJ, GuX, . Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol. 2000; 164: 3368–3376.
38.
TremblayK, LemireM, ProvostV, . Association study between the CX3CR1 gene and asthma. Genes Immun. 2006; 7: 632–641.
39.
HosokawaY, NakanishiT, YamaguchiD, . Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Clin Exp Immunol. 2005; 139: 506–512.
40.
RuthJH, RottmanJB, KatschkeKJ, . Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum. 2001; 44: 2750–2760.
